Lumos Diagnostics Holdings (ASX:LDX) and Hologic agreed to expand the scope of work for the new fetal fibronectin test, according to a Monday Australian bourse filing.
The expanded scope of work relates to phase 3 of the development agreement, which focuses on delivery of the system prototype and will include the incorporation of additional hardware features into the proprietary reader technology.
This is expected to generate additional fee revenue for Lumos of between $600,000 to $800,000.
Phase 2 of the development agreement is expected to complete around April. The phase seeks to demonstrate that the assay can detect a biomarker.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.